How much is too much? Outcomes in patients using high-dose insulin glargine

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacotherapy

Background:

• Many patients with type 2 diabetes mellitus (T2DM) fail to reach glycemic targets with basal insulin alone.
• Investigating factors influencing treatment outcomes in T2DM is crucial for optimizing patient care.

Purpose of the Study:

• To analyze characteristics and clinical outcomes of T2DM patients on high-dose insulin glargine.
• To evaluate the impact of oral antidiabetes drugs (OADs) used concurrently with high-dose insulin glargine.

Main Methods:

• Pooled patient-level data from 15 randomized, treat-to-target trials of insulin glargine ± OADs in T2DM.
• Stratification of patients based on insulin glargine dose thresholds (>0.5, >0.7, >1.0 IU/kg).
• Assessment of glycated hemoglobin A1c (A1C), fasting plasma glucose, body weight, and hypoglycemia events.

Main Results:

• Patients exceeding insulin dose cut-offs had higher baseline A1C, were younger, had shorter diabetes duration, and experienced greater weight gain.
• Concomitant metformin monotherapy resulted in higher insulin doses but improved A1C, reduced weight gain, and lowered hypoglycemia rates compared to sulfonylurea combinations.
• These findings were consistent regardless of whether insulin dose cut-offs were exceeded.

Conclusions:

• Increasing basal insulin doses beyond 0.5 IU/kg may offer limited additional glycemic benefit in T2DM.
• Consideration of treatment strategies focused on postprandial glucose control is warranted for patients on high-dose basal insulin.
• Metformin monotherapy appears more advantageous than sulfonylurea combinations when used with insulin glargine in T2DM.